SDC2 and cancer: Heparin analogues have been investigated for their effectiveness in interfering with HSPG functions and have also been tested in cancer patients, not only for the treatment of cancer-associated thromboembolism but also for their potential effects on cancer growth and metastasis (Ma et al., 2020; Mohamed and Coombe, 2017).